- In April 2023, BioMérieux, a global leader in in-vitro diagnostics, launched its advanced VIDAS Gastrointestinal Panel, a rapid immunoassay solution for the detection of major gastroenteritis-causing pathogens. The panel is designed to deliver quick and accurate results for both bacterial and viral strains, enhancing diagnostic efficiency in clinical settings. This innovation strengthens BioMérieux’s position in the molecular diagnostics space and aligns with the growing demand for multiplex testing in gastrointestinal disease management
- In March 2023, QuidelOrtho Corporation announced the expansion of its Sofia 2 Analyzer platform with a new test for norovirus detection. The launch is intended to meet the increasing need for rapid diagnostics in outpatient clinics and emergency departments, particularly during seasonal outbreaks. With a turnaround time of under 15 minutes, this addition underscores QuidelOrtho’s commitment to developing reliable, point-of-care solutions for acute gastroenteritis cases
- In March 2023, Thermo Fisher Scientific Inc. unveiled its latest TaqPath Enteric Pathogen Panels, offering real-time PCR-based multiplex testing for gastrointestinal pathogens. Designed for high-throughput laboratories, the panels cover a wide array of viral, bacterial, and parasitic targets. This launch addresses growing concerns over antimicrobial resistance by supporting more precise pathogen identification, further reinforcing Thermo Fisher’s leadership in molecular diagnostics innovation
- In February 2023, Luminex Corporation announced a partnership with a consortium of public health labs in Southeast Asia to deploy its xTAG Gastrointestinal Pathogen Panel (GPP) for enhanced disease surveillance. The initiative is aimed at improving diagnostic capabilities in regions with high gastroenteritis prevalence, and emphasizes Luminex’s role in advancing molecular diagnostic access in underserved markets
- In January 2023, Cepheid, a subsidiary of Danaher Corporation, received regulatory clearance for its Xpert Xpress Gastro Panel in the European market. The panel enables rapid, cartridge-based detection of multiple enteric pathogens using minimal hands-on time. Designed to support decentralized testing environments such as urgent care centers and remote hospitals, this development highlights Cepheid’s focus on combining speed, accuracy, and accessibility to improve clinical outcomes in gastroenteritis management
